HEALTHCARE RESOURCE USE AND COSTS OF CARE IN HR+/HER2-METASTATIC BREAST CANCER: A RETROSPECTIVE US CLAIMS DATA STUDY

被引：0
|
作者：
Collin, S. [1 ]
Tse, J. [2 ]
Shaikh, N. F. [3 ]
Near, A. [2 ]
Hamilton, E. [4 ]
Brufsky, A. [5 ]
Gradishar, W. [6 ]
Mehta, S. [7 ]
Long, G. H. [1 ]
Toms, N. [1 ]
机构：
[1] AstraZeneca Pharmaceut Ltd, Cambridge, England
[2] IQVIA, Durham, NC USA
[3] IQVIA, Morgantown, WV USA
[4] Sarah Cannon Res Inst, Nashville, TN USA
[5] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA
[6] Northwestern Univ, Feinberg Sch Med, Chicago, IL USA
[7] Daiichi Sankyo, Basking Ridge, NJ USA
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE417
引用
收藏
页码：S134 / S134
页数：1
相关论文
共 50 条
  • [31] Patient and treatment characteristics in HR+/HER2-metastatic breast cancer in a real-life setting
    Karadurmus, Nuri
    Sendur, Mehmet Ali Nahit
    Cil, Timucin
    Oksuzoglu, Omur Berna Cakmak
    Arslan, Cagatay
    Harputluoglu, Hakan
    Goksu, Sema Sezgin
    Ozturk, Banu
    MevludeInanc
    Cubukcu, Erdem
    Demirci, Umut
    Erdem, Dilek
    Cihan, Sener
    Tural, Deniz
    Dumludag, Aysegul
    Yilmaz, Funda
    Avsar, Esin
    Sonusen, Sermin Dinc
    Ozturk, Ozge Fulya
    Aver, Birkan
    Kaplan, Muhammet Ali
    CANCER RESEARCH, 2023, 83 (05)
  • [32] The association between age, toxicity and outcomes of abemaciclib treatment in HR+/HER2-metastatic breast cancer
    Ovcaricek, Tanja
    Matos, Erika
    Borstnar, Simona
    Ribnikar, Domen
    Kuhar, Cvetka Grasic
    Cankar, Kaja
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [33] Current Treatment Patterns Among Postmenopausal Women with HR+/HER2-Metastatic Breast Cancer in US Community Oncology Practices: An Observational Study
    Goldschmidt, Deborah
    Dalal, Anand A.
    Romdhani, Hela
    Kelkar, Sneha
    Guerin, Annie
    Gauthier, Genevieve
    Wu, Eric Q.
    Niravath, Polly
    Small, Tania
    ADVANCES IN THERAPY, 2018, 35 (04) : 482 - 493
  • [34] Treatment patterns and characteristics of postmenopausal women with HR+/HER2-metastatic breast cancer receiving everolimus
    Vekeman, Francis
    Hao, Yanni
    Cheng, Wendy Y.
    Fortier, Jonathan
    Robitaille, Marie-Noelle
    Duh, Mei Sheng
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2015, 24 : 114 - 115
  • [35] Dosing Patterns and Economic Burden of Palbociclib Drug Wastage in HR+/HER2-Metastatic Breast Cancer
    Dalal, Anand A.
    Gagnon-Sanschagrin, Patrick
    Burne, Rebecca
    Guerin, Annie
    Gauthier, Genevieve
    Small, Tania
    Niravath, Polly
    ADVANCES IN THERAPY, 2018, 35 (06) : 768 - 778
  • [36] Time on treatment of everolimus versus endocrine monotherapy or chemotherapy for early-line treatment of HR+/HER2-metastatic breast cancer: A retrospective chart review study in the US
    Li, N.
    Ohashi, E.
    Koo, V.
    Xie, J.
    Hao, Y.
    Tang, D. H.
    CANCER RESEARCH, 2017, 77
  • [37] Unmet need in heavily pre-treated patients with HR+/HER2-metastatic breast cancer (mBC) in the US: A ConcertAI analysis
    Waks, A. G.
    Gharaibeh, M.
    Sjekloca, N.
    Poluparthi, N.
    Shah, A.
    Bergamaco, E.
    MacCannell, T.
    Leung, G.
    Ntalla, I.
    Oko-osi, H.
    Tolaney, S. M.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S653 - S653
  • [38] Comparison of medical costs and healthcare resource utilization of post-menopausal women with HR+/HER2- metastatic breast cancer receiving everolimus-based therapy or chemotherapy: a retrospective claims database analysis
    Li, Nanxin
    Hao, Yanni
    Koo, Valerie
    Fang, Anna
    Peeples, Miranda
    Kageleiry, Andrew
    Wu, Eric Q.
    Guerin, Annie
    JOURNAL OF MEDICAL ECONOMICS, 2016, 19 (04) : 414 - 423
  • [39] Initial real world treatment patterns and outcomes of Abemaciclib for the treatment of HR+,HER2-metastatic breast cancer
    Carter, Gebra Cuyun
    Sheffield, Kristin M.
    Gossai, Anala
    Huang, Yu-Jing
    Zhu, Yajun Emily
    Bowman, Lee
    Smith, Emily Nash
    Mathur, Raina
    Cohen, Aaron B.
    Baxi, Shrujal
    Rybowski, Sarah
    Chong, Amy Lee
    Seidman, Andrew D.
    CANCER RESEARCH, 2020, 80 (04)
  • [40] Abemaciclib for treating patients with HR+/HER2-metastatic breast cancer: a real-world study in France, Italy and Spain
    Blancas, Isabel
    Grosjean, Jessica
    Pedersini, Rebecca
    Buzzoni, Carlotta
    Sleilaty, Ghassan
    Molero, Alberto
    Tamma, Antonella
    Chouaki, Nadia
    Atienza, Manuel
    Emde, Anna
    Siddi, Sara
    Bayona, Rodrigo Sanchez
    Del Mastro, Lucia
    Fakhouri, Walid
    FUTURE ONCOLOGY, 2024,
12345